Nasdaq: KLRA

Kailera Therapeutics, Inc. (KLRA)

Kailera Therapeutics, Inc. is a public company that reports to the U.S. Securities and Exchange Commission and trades on Nasdaq under the ticker KLRA. Bright Analyst brings its financial statements, SEC filings, stock performance, news and peer comparisons together in one place, with AI analysis throughout.

Key facts

Ticker symbol
KLRA
Exchange
Nasdaq
SEC CIK
2096997
Official filings
SEC EDGAR

Research KLRA

  • Profile — Business description, headquarters, subsidiaries and corporate identifiers.
  • Financials — Income statement, balance sheet and cash flow from 10-K and 10-Q filings.
  • SEC Filings — Every 10-K, 10-Q and 8-K, readable inline with AI analysis.
  • Stock Analysis — Price chart, returns, technical indicators and related companies.
  • News — Latest headlines and press coverage.
  • Material Contracts — Material agreements filed as exhibits to SEC reports.
  • Benchmark — Stock performance against the S&P 500, Nasdaq-100 and Dow (through SPY, QQQ and DIA) and economic indicators.
  • Peer Comparison — Side-by-side financial ratios against industry peers.

Frequently asked questions

What is Kailera Therapeutics, Inc.'s stock ticker?

Kailera Therapeutics, Inc. trades under the ticker symbol KLRA on Nasdaq. Its SEC Central Index Key (CIK) is 2096997.

Where can I read Kailera Therapeutics, Inc.'s SEC filings?

The KLRA SEC Filings page lists the 10-K annual reports, 10-Q quarterly reports and 8-K current reports Kailera Therapeutics, Inc. has filed, with AI analysis. The original documents are also on SEC EDGAR.

How can I analyze KLRA's financial statements?

The KLRA Financials page shows Kailera Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly, taken from its XBRL filings, with an AI analysis of each statement.

How does KLRA compare with its peers and the market?

The KLRA Peer Comparison page lines Kailera Therapeutics, Inc. up against industry peers on valuation, growth and profitability ratios, and the Benchmark page compares its stock with the S&P 500, the Nasdaq-100 and the Dow.

For information only — not investment advice.